In contrast, we found that RAD21 mutations are associated with de novo AML, are rarely preceded by MDS or MDS/MPN, and are associated with de novo or pan AML molecular abnormalities, such as t(8;21), FLT3, and NPM1 mutations [24]. The gene discussed is FLT3; the disease is myelodysplastic syndrome.